1.Study on the serum levels change of vascular endothelial growth factor during operation of non-small-cell lung cancer
Lincan DUAN ; Yunchao HUANG ; Gaofeng LI ; Anning CHEN ; Guangqiang ZHAO ; Zhengwei WU
Cancer Research and Clinic 2008;20(5):324-326
Objective To investigate the serum levels change of vascular endothelial growth factor (VEGF) during operation of non-small-cell lung cancer (NSCLC). Methods 120 cases of NSCLC patient diagnosed by pathology as well as with operation indication were selected as the experimental group. The patients selected were required without any chemotherapy or radiotherapy before operation, besides that, they should have good compliance and free will to be examined. During the process of experiment, 60 cases concluded as healthy in the physical examination were chosen as control group. The correlative information of the experimental group were collected including periphery blood specimen collected in 3 days before the operation, and of the 1st day, 7th day and 30th day after the operation while the periphery blood specimen of control group were collected. The serum levels of VEGF were detected by adopting enzyme linked immunosorbent assay (ELISA) method. Results The serum levels of VEGF in NSCLC patients before operation, of the first postoperative day, of the seventh postoperative day and of the thirtieth postoperative day were significantly higher than that in healthy people (P<0.01), respectively (279.14±44.89)μg/L, (282.70±42.74) μg/L, (353.79±44.55) μg/L, (178.40±43.43) μg/L and (91.40±16.55) μg/L. The serum levels of VEGF in NSCLC patients showed positive correlation with the stages (P<0.01). Conclusion The serum levels of VEGF in NSCLC patients scale up. At the same time it shows positive correlation with the stages of the primary tumor. The serum levels of VEGF in NSCLC patients scales up by degrees in one week after the operation, and drop one month later.
2.Levels of activation markers of platelets in peripheral blood and their significance in patients with lung cancer.
Yong ZHANG ; Lincan DUAN ; Xudong XIANG ; Yunchao HUANG ; Kebao QIAN ; Yongxin JIANG ; Kun WANG
Chinese Journal of Lung Cancer 2007;10(3):216-218
BACKGROUNDPlatelet activation often occurs in intermediate and advanced tumors, with increases of expression and release of platelet adhesion molecule. The aim of this study is to investigate the expression of activation markers of platelet and their significance in lung cancer.
METHODSThe activation markers of platelet, CD62P and CD63, were detected in peripheral blood of 120 patients with lung cancer and 60 healthy persons by FCM method.
RESULTSThe levels of peripheral blood CD62P and CD63 of lung cancer patients were significantly higher than those of healthy people (P < 0.01). In lung cancer group, the levels of peripheral blood CD62P and CD63 on the seventh postoperative day were significantly lower than those before operation and on the first postoperative day (P < 0.01). The levels of peripheral blood CD62P and CD63 before operation were closely related to size of tumor, lymph node status and TNM stages (P < 0.01), but not to cell differentiation, histology, age and sex of lung cancer patients (P > 0.05).
CONCLUSIONSActivation markers of platelet obviously increase in peripheral blood of lung cancer patients and they may play important roles in tumor growth and lymphatic metastasis. The levels of activation markers of platelet may be useful predictors for prognosis.
3.Research on fast track surgery application in lung cancer surgery.
Guangqiang ZHAO ; Yunchao HUANG ; Xiaobo CHEN ; Lincan DUAN ; Qianli MA ; Yujie LEI ; Kaiyun YANG ; Jiyang WANG
Chinese Journal of Lung Cancer 2010;13(2):102-106
BACKGROUND AND OBJECTIVEFast track surgery (FTS) is a systematical method to accelerate the recovery of surgical patients by reducing the physical and mental trauma stress of them. The research is to investigate the feasibility of FTS application in lung cancer surgery.
METHODSA total of 80 cases of lung cancer patients with single leaf lobotomy resection were randomized into two groups. While the experimental group was treated with the conception of FTS, and the control group was treated with the traditional methods. The incident rate of post-operation pain degrees, telecasts, pleural effusion, the post-operation time stay in hospital time and the total cost during hospitalization in two groups were compared respectively.
RESULTSIn FTS group: the VAS score of post-operation pain at 1 h, 6 h, 12 h, 24 h and 48 h all significantly decreased compared to the traditional therapy group. The incidence rate of telecast was 10.53%. The incidence rate of pleural effusion was 26.31%. The length of stay after operation was (4 +/- 1) d and the total cost was RMB 15 600 +/- 7 600. In the control group, the above values were 77.78%, 33.33%, 22.22%, (9 +/- 1) d, RMB 23 600 +/- 5 400, respectively. The post operation pain (VAS method) of FTS group was remarkablely below the control group. There has significant difference of the incident rate of telecasts, stay time in hospital and the total cast in two groups (P < 0.05). No significant difference was observed in the incident rate ofpleural effusion.
CONCLUSIONThe new methods of FTS can apparently accelerates recovery after lung cancer resection, reduces complications, shorten timestay in hospital and cut down the total cost.
Adult ; Aged ; Female ; Humans ; Lung Neoplasms ; surgery ; Male ; Middle Aged ; Pulmonary Surgical Procedures ; Treatment Outcome
4.MicroRNA-125b and cancer
Qianqian LIU ; Xiaolan HE ; Lin TANG ; Yixiao YUAN ; Shun QIU ; Lincan DUAN
Journal of International Oncology 2020;47(2):90-92
MicroRNA-125b (miR-125b) has been proved to be closely related to a variety of cancers in recent years, such as lung cancer, digestive system cancers, blood cancers, etc. miR-125b plays a key role in the occurrence and development of cancers, which can evaluate the therapeutic effects of various treatment methods of cancers by detecting the expression of miR-125b, and can assist in the diagnosis of cancers. It is of great significance to explore the mechanism of miR-125b in cancers for the treatment.